Novartis researchers use automation to rapidly identify starting points for new drugs.

Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

An antibody that boosts muscle mass could mean independence for the frail and elderly. Learn how Novartis research aims to improve healthy aging.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.

Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.

Ann Aerts has stared death in the eye. The head of the non-profit Novartis Foundation lost colleagues when she was serving as an emergency medicine physician on a medical mission in a dangerously unstable country.